Blog

News &
Updates

Revital Healthcare banks blanket contract
from a key global organisation

Revital Healthcare has recently secured a notable contract with a global organization to supply India with 50 million units of 2ML vaccine syringes amidst concerns over a shortage of this precious commodity. Following a highly competitive bidding process, Revital emerged as the winning candidate for the tender valued at Sh150 million, beating out several other leading manufacturers. This recent development has made the company Africa’s largest medical device manufacturer.

The pressing shortage of various types of syringes has led Revital Healthcare to offer the 0.5ML Auto-Disable Syringe as a viable alternative solution for vaccination purposes on a global scale. The Kenyan-based medical supply manufacturer is well-equipped to meet this challenge, as it produces both two-part and three-part 2ml syringes, for which it has received contracts for both.

Furthermore, several major organizations have shown their confidence in Revital by awarding the firm a blanket contract for the entire year of 2022, reserving 100% of the 0.5ml syringes produced. As a leading local manufacturer, Revital has consistently expressed its readiness to assist the government in its efforts to combat the ongoing global pandemic.

Speaking to a Kenya news agency, Ronnek Vora, Revital’s Sales and Marketing Director,  emphasized that this a win for Kenya as well.

They have identified the 2ml because of the low dead space on the syringe so they can utilize the entire vial for the dosage of the patients. We continually ask for the government’s support because by supporting us, they are supporting the 500 people working in this factory. This is a plus for Kenya as a country and President Uhuru’s legacy of Buy Kenya, Build Kenya,

Roneek Vora,
Sales, Marketing & Development Director at Revital Healthcare

The establishment commenced operations in 2008, with a solitary product, but it has since expanded to offer 45 distinct products, consisting of over 500 Stock Keeping Units (SKUs). The corporation’s achievement of exporting vaccine syringes to India is a momentous milestone, not only for the company but also for Kenya as a whole. This is an unprecedented occurrence in history, and it has positioned the leading medical supply manufacturer to prepare for the imminent demand for vaccine syringes. This surge in demand has been catalyzed by a Sh440 million grant bestowed upon them by the Bill and Melinda Gates Foundation. The grant will be utilized to manufacture the 0.5ml auto-disable syringes, which have been designated as the global standard for administering Covid-19 vaccinations.

As of 2013, Revital Healthcare has been consistently producing an average of 74 million syringes yearly. However, given the current upsurge in global demand for vaccine syringes, the firm will be compelled to triple its production output to approximately 320 million syringes annually. This growth trajectory will necessitate the hiring of more personnel, and the company has already declared that it will be recruiting at least 100 new employees to cater to the augmented demand.

“We are planning to increase production further by another 100 -150 million by the following year. As per our promise to the foundation, we are going to re-invest our funds from these products to expand our product range. This will create more than 5,000 other jobs indirectly,

Roneek Vora,
Sales, Marketing & Development Director at Revital Healthcare

 

There is a projected possible deficit of approximately 2.2 billion auto-dispensable Covid-19 vaccine syringes worldwide by 2022. This potential shortfall has been attributed to several factors, including a surge in demand for syringes, interruptions to international freight and supply chains, an irregular supply of vaccines due to a substantial reliance on donated doses, and national restrictions on the exportation of syringes. Moreover, with the impending release of malaria vaccines next year, the demand for the specific 0.5ml vaccine syringes is expected to soar even higher. Despite the pivotal role of syringes in vaccine administration, the world has overly focused on the vaccines themselves, overlooking the critical role of syringes in ensuring universal vaccine access.

Ronnek Vora further stated that Revital aims to reduce this major gap as fast as possible. Meanwhile, Revital Healthcare has been actively advocating for governments worldwide to place equal emphasis on syringes as they do on vaccines.

With this deficit of up to 4 billion syringes, we want to reduce this gap as much as possible because most of the vaccine syringes will be coming to Africa. Since March last year, we have been telling the world they are focusing too much on vaccines but no one is looking at syringes and that there is going to be a shortfall for this product. Today, we are witnessing the shortfall.

Roneek Vora,
Sales, Marketing & Development Director at Revital Healthcare

More From This Category

WHO PQS

WHO PQS

Press ReleaseRevital Healthcare EPZ Ltd. Achieves WHO Prequalification for Early-Activation Auto-Disable Syringe: A Milestone for African Manufacturing and Immunization ProgrammingRevital Healthcare EPZ Ltd. stands as the exclusive African manufacturer granted WHO PQ...

Ukraine using Revital-made bCPAP device to save premature babies

Ukraine using Revital-made bCPAP device to save premature babies

Blog News &UpdatesUkraine using Revital-made bCPAP device to save premature babiesPremature babies in Ukraine with breathing difficulties are being saved by a device made in Kenya. The bCPAP device, produced by Africa's largest medical manufacturer - Revital...